{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T05:19:34Z","timestamp":1770441574312,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T00:00:00Z","timestamp":1767052800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Natural Science Foundation of Zhejiang Province, China","award":["ZCLQ24B0502"],"award-info":[{"award-number":["ZCLQ24B0502"]}]},{"name":"the Medical and public health projects in Zhejiang Province","award":["2025KY691"],"award-info":[{"award-number":["2025KY691"]}]},{"name":"Zhejiang Province disease prevention and control science and technology project","award":["2025JK205"],"award-info":[{"award-number":["2025JK205"]}]},{"name":"the \u201cPioneer\u201d and \u201cLeading Goose\u201d R&D Program of Zhejiang Province","award":["2024C03082"],"award-info":[{"award-number":["2024C03082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is usually treated with gemcitabine (GEM)-based chemotherapy. However, resistance to GEM develops frequently. Aberrant fibroblast growth factor receptors (FGFR) signaling in PDAC is linked to advanced tumor stages and poor prognosis, making it a potential therapeutic target. This study aimed to explore whether inhibition of FGFR by derazantinib could reduce the resistance to GEM in PDAC. Human AsPC-1 and BxPC-3 PDAC cell lines were screened against a panel of FDA-approved compounds to identify the potential drug. Gem-resistant cell lines were subsequently utilized to validate the efficacy of derazantinib. The synergistic interaction between derazantinib and GEM was confirmed through combination-index analysis, clonogenic assays, and apoptosis assays. With RNA-seq, immunohistochemistry, Western blotting, and animal experiments, the effects of derazantinib on the malignant behaviors, signaling pathways in GEM-resistant PDAC cells and tumors were examined. Treatment with derazantinib and GEM synergistically inhibited the malignant behaviors of GEM-resistant PDAC cells and tumor growth by downregulating FGFR2 and FGFR3 expression. RNA-seq revealed upregulated MUC5AC expression in GEM-resistant PDAC, which was attenuated by derazantinib through inhibiting the MAPK and NF-\u03baB signaling. Furthermore, higher levels of FGFR2 and FGFR3 expression were associated with worse survival of PDAC patients and negatively correlated with tumor differentiation. Moreover, the combination of derazantinib and GEM significantly inhibited the growth of GEM-resistant PDAC tumors in vivo. The data highlighted that higher levels of FGFR2, FGFR3, and MUC5AC expression promoted the progression and resistance to GEM in PDAC. Derazantinib treatment enhanced the sensitivity to GEM by attenuating the NF-\u03baB and MAPK pathways to inhibit MUC5AC expression. Therefore, derazantinib may be a promising chemotherapeutic adjuvant for treating PDAC, particularly for patients with GEM resistance.<\/jats:p>","DOI":"10.1007\/s12032-025-03222-1","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T07:13:49Z","timestamp":1767078829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-\u03baB and MAPK pathways to suppress MUC5AC expression"],"prefix":"10.1007","volume":"43","author":[{"given":"Wenkai","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiyun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lue","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junnan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangyue","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaju","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimiao","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,30]]},"reference":[{"issue":"5","key":"3222_CR1","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology. 2023;164(5):752\u201365.","journal-title":"Gastroenterology"},{"issue":"16","key":"3222_CR2","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1097\/CM9.0000000000003225","volume":"137","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, et al. Burden of six major types of digestive system cancers globally and in China. Chin Med J (Engl). 2024;137(16):1957\u201364.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"3222_CR3","first-page":"10","volume":"75","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, et al. Cancer statistics, 2025. CA Cancer J Clin. 2023;75(1):10\u201345.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"3222_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1470-2045(23)00516-8","volume":"25","author":"B Gyawali","year":"2024","unstructured":"Gyawali B, Booth CM. Treatment of metastatic pancreatic cancer: 25 years of innovation with little progress for patients. Lancet Oncol. 2024;25(2):167\u201370.","journal-title":"Lancet Oncol"},{"issue":"2","key":"3222_CR5","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/SLA.0000000000002753","volume":"270","author":"G Gemenetzis","year":"2019","unstructured":"Gemenetzis G, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270(2):340\u20137.","journal-title":"Ann Surg"},{"issue":"10242","key":"3222_CR6","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","volume":"395","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi JD, et al. Pancreatic cancer. Lancet. 2020;395(10242):2008\u201320.","journal-title":"Lancet"},{"key":"3222_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102486","author":"T Koltai","year":"2022","unstructured":"Koltai T, et al. Resistance to gemcitabine in pancreatic ductal adenocarcinoma: a physiopathologic and pharmacologic review. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14102486.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"3222_CR8","doi-asserted-by":"publisher","first-page":"C540","DOI":"10.1152\/ajpcell.00331.2022","volume":"324","author":"AK Beutel","year":"2023","unstructured":"Beutel AK, Halbrook CJ. Barriers and opportunities for gemcitabine in pancreatic cancer therapy. Am J Physiol Cell Physiol. 2023;324(2):C540\u201352.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"7","key":"3222_CR9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1053\/j.gastro.2023.02.025","volume":"164","author":"X Jiang","year":"2023","unstructured":"Jiang X, et al. Targeting UBE2T potentiates gemcitabine efficacy in pancreatic cancer by regulating pyrimidine metabolism and replication stress. Gastroenterology. 2023;164(7):1232\u201347.","journal-title":"Gastroenterology"},{"issue":"12","key":"3222_CR10","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-19-3975","volume":"27","author":"G Yang","year":"2021","unstructured":"Yang G, et al. Integrative genomic analysis of gemcitabine resistance in pancreatic cancer by Patient-derived xenograft models. Clin Cancer Res. 2021;27(12):3383\u201396.","journal-title":"Clin Cancer Res"},{"key":"3222_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.drup.2015.10.002","volume":"23","author":"Y Binenbaum","year":"2015","unstructured":"Binenbaum Y, Na\u2019ara S, Gil Z. Gemcitabine resistance in pancreatic ductal adenocarcinoma. Drug Resist Updat. 2015;23:55\u201368.","journal-title":"Drug Resist Updat"},{"issue":"14","key":"3222_CR12","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1002\/cncr.26661","volume":"118","author":"ME Valsecchi","year":"2012","unstructured":"Valsecchi ME, et al. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma. Cancer. 2012;118(14):3484\u201393. https:\/\/doi.org\/10.1002\/cncr.26661.","journal-title":"Cancer"},{"issue":"2","key":"3222_CR13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4103\/2303-9027.117692","volume":"2","author":"R Angelescu","year":"2013","unstructured":"Angelescu R, et al. Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis. Endosc Ultrasound. 2013;2(2):86\u201391.","journal-title":"Endosc Ultrasound"},{"key":"3222_CR14","doi-asserted-by":"publisher","first-page":"101064","DOI":"10.1016\/j.drup.2024.101064","volume":"73","author":"Q Lin","year":"2024","unstructured":"Lin Q, et al. Fibroblast growth factor receptor 1 Inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness. Drug Resist Updat. 2024;73:101064.","journal-title":"Drug Resist Updat"},{"issue":"3","key":"3222_CR15","doi-asserted-by":"publisher","first-page":"e12605","DOI":"10.1111\/cpr.12605","volume":"52","author":"X Kang","year":"2019","unstructured":"Kang X, et al. Deciphering role of FGFR signalling pathway in pancreatic cancer. Cell Prolif. 2019;52(3):e12605.","journal-title":"Cell Prolif"},{"issue":"2","key":"3222_CR16","doi-asserted-by":"publisher","first-page":"275","DOI":"10.3390\/biom15020275","volume":"15","author":"R Dieli","year":"2025","unstructured":"Dieli R, et al. The oncoprotein mucin 1 in pancreatic cancer onset and progression: potential clinical implications. Biomolecules. 2025;15(2):275.","journal-title":"Biomolecules"},{"issue":"1","key":"3222_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.gastro.2021.09.017","volume":"162","author":"K Ganguly","year":"2022","unstructured":"Ganguly K, et al. Mucin 5AC serves as the nexus for beta-Catenin\/c-Myc interplay to promote glutamine dependency during pancreatic cancer chemoresistance. Gastroenterology. 2022;162(1):253\u201368. e13.","journal-title":"Gastroenterology"},{"issue":"60","key":"3222_CR18","doi-asserted-by":"publisher","first-page":"101175","DOI":"10.18632\/oncotarget.20933","volume":"8","author":"CJ Liou","year":"2017","unstructured":"Liou CJ, Huang WC. Casticin inhibits interleukin-1beta-induced ICAM-1 and MUC5AC expression by blocking NF-kappaB, PI3K-Akt, and MAPK signaling in human lung epithelial cells. Oncotarget. 2017;8(60):101175\u201388.","journal-title":"Oncotarget"},{"issue":"10","key":"3222_CR19","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1016\/j.ajpath.2019.06.007","volume":"189","author":"C Raggi","year":"2019","unstructured":"Raggi C. Antitumor activity of a novel fibroblast growth factor receptor inhibitor for intrahepatic cholangiocarcinoma. Am J Pathol. 2019;189(10):2090\u2013101.","journal-title":"Am J Pathol"},{"issue":"11","key":"3222_CR20","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1080\/13543784.2021.1995355","volume":"30","author":"S Braun","year":"2021","unstructured":"Braun S, et al. Derazantinib: an investigational drug for the treatment of cholangiocarcinoma. Expert Opin Investig Drugs. 2021;30(11):1071\u201380.","journal-title":"Expert Opin Investig Drugs"},{"key":"3222_CR21","doi-asserted-by":"publisher","first-page":"100930","DOI":"10.1016\/j.drup.2023.100930","volume":"67","author":"X Li","year":"2023","unstructured":"Li X, et al. Thiol oxidative stress-dependent degradation of transglutaminase2 via protein S-glutathionylation sensitizes 5-fluorouracil therapy in 5-fluorouracil-resistant colorectal cancer cells. Drug Resist Updat. 2023;67:100930.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"3222_CR22","doi-asserted-by":"publisher","first-page":"38","DOI":"10.14348\/molcells.2020.0188","volume":"44","author":"SU Lee","year":"2021","unstructured":"Lee SU, et al. Transforming growth factor beta inhibits MUC5AC expression by Smad3\/HDAC2 complex formation and NF-kappaB deacetylation at K310 in NCI-H292 cells. Mol Cells. 2021;44(1):38\u201349.","journal-title":"Mol Cells"},{"key":"3222_CR23","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.2147\/JAA.S316250","volume":"14","author":"X Chen","year":"2021","unstructured":"Chen X, et al. Muc5ac production inhibited by decreased LncRNA H19 via PI3K\/Akt\/NF-\u03baB in asthma. J Asthma Allergy. 2021;14:1033\u201343.","journal-title":"J Asthma Allergy"},{"issue":"4","key":"3222_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/jpi.12127","volume":"56","author":"IS Shin","year":"2014","unstructured":"Shin IS, et al. Melatonin inhibits MUC5AC production via suppression of MAPK signaling in human airway epithelial cells. J Pineal Res. 2014;56(4):398\u2013407.","journal-title":"J Pineal Res"},{"issue":"9","key":"3222_CR25","first-page":"851","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic Cancer: Rev JAMA. 2021;326(9):851\u201362.","journal-title":"Pancreatic Cancer: Rev JAMA"},{"issue":"11","key":"3222_CR26","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","volume":"8","author":"T Conroy","year":"2022","unstructured":"Conroy T, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8(11):1571\u20138.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3222_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1186\/s12967-024-05528-6","volume":"22","author":"MM Konate","year":"2024","unstructured":"Konate MM, et al. Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts. J Transl Med. 2024;22(1):733.","journal-title":"J Transl Med"},{"issue":"12","key":"3222_CR28","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1021\/acs.jproteome.3c00463","volume":"22","author":"S Rasam","year":"2023","unstructured":"Rasam S, et al. Highly reproducible quantitative proteomics analysis of pancreatic cancer cells reveals proteome-level effects of a novel combination drug therapy that induces cancer cell death via metabolic remodeling and activation of the extrinsic apoptosis pathway. J Proteome Res. 2023;22(12):3780\u201392.","journal-title":"J Proteome Res"},{"key":"3222_CR29","doi-asserted-by":"publisher","first-page":"216997","DOI":"10.1016\/j.canlet.2024.216997","volume":"595","author":"Y Ito","year":"2024","unstructured":"Ito Y, et al. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma. Cancer Lett. 2024;595:216997.","journal-title":"Cancer Lett"},{"issue":"9","key":"3222_CR30","first-page":"2196","volume":"18","author":"I Kawahara","year":"2024","unstructured":"Kawahara I, et al. Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. Mol Oncol. 2024;18(9):2196\u2013211.","journal-title":"Mol Oncol"},{"issue":"11","key":"3222_CR31","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/bjc.2017.330","volume":"117","author":"KP Papadopoulos","year":"2017","unstructured":"Papadopoulos KP, et al. A phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours. Br J Cancer. 2017;117(11):1592\u20139.","journal-title":"Br J Cancer"},{"issue":"5","key":"3222_CR32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671\u201384.","journal-title":"Lancet Oncol"},{"issue":"21","key":"3222_CR33","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389(21):1961\u201371.","journal-title":"N Engl J Med"},{"issue":"11","key":"3222_CR34","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","volume":"23","author":"ZA Wainberg","year":"2022","unstructured":"Wainberg ZA, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430\u201340.","journal-title":"Lancet Oncol"},{"issue":"10","key":"3222_CR35","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.6004\/jnccn.2022.7039","volume":"20","author":"CF Ng","year":"2022","unstructured":"Ng CF, et al. Exceptional response to erdafitinib in FGFR2-Mutated metastatic pancreatic ductal adenocarcinoma. J Natl Compr Canc Netw. 2022;20(10):1076\u20139.","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"3222_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.759","volume":"9","author":"S Santorelli","year":"2021","unstructured":"Santorelli S, et al. In vivo effects of AZD4547, a novel fibroblast growth factor receptor inhibitor, in a mouse model of endometriosis. Pharmacology Research & Perspectives. 2021;9(2):e00759.","journal-title":"Pharmacology Research & Perspectives"},{"issue":"29","key":"3222_CR37","doi-asserted-by":"publisher","first-page":"15905","DOI":"10.1002\/anie.202101328","volume":"60","author":"G Du","year":"2021","unstructured":"Du G, Jiang J, et al. Discovery of a potent degrader for fibroblast growth factor receptor 1\/2. Angew Chem Int Ed Engl. 2021;60(29):15905\u201311.","journal-title":"Angew Chem Int Ed Engl"},{"key":"3222_CR38","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.freeradbiomed.2024.07.002","volume":"222","author":"X Zhu","year":"2024","unstructured":"Zhu X, Wang L, et al. Erdafitinib promotes ferroptosis in human uveal melanoma by inducing ferritinophagy and lysosome biogenesis via modulating the FGFR1\/mTORC1\/TFEB signaling axis. Free Radic Biol Med. 2024;222:552\u201368.","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"3222_CR39","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/cells10061342","volume":"10","author":"P Szybowska","year":"2021","unstructured":"Szybowska P, et al. Negative regulation of FGFR (Fibroblast growth factor receptor) signaling. Cells. 2021;10(6):1342.","journal-title":"Cells"},{"issue":"1","key":"3222_CR40","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13058-025-02086-7","volume":"27","author":"Q Luo","year":"2025","unstructured":"Luo Q, et al. Erdafitinib inhibits the tumorigenicity of MDA-MB-231 triple-negative breast cancer cells by inducing TRIM25\/ubiquitin-dependent degradation of FGFR4. Breast Cancer Res. 2025;27(1):128.","journal-title":"Breast Cancer Res"},{"key":"3222_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002342","author":"Y He","year":"2025","unstructured":"He Y, et al. Clinical efficacy and chemoresistance analysis of precision neoadjuvant chemotherapy for borderline resectable pancreatic cancer: a prospective, single-arm pilot study. Int J Surg. 2025. https:\/\/doi.org\/10.1097\/JS9.0000000000002342.","journal-title":"Int J Surg"},{"key":"3222_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-259660","author":"Z Rubnitz","year":"2025","unstructured":"Rubnitz Z, et al. Gemcitabine-induced myositis in a patient with pancreatic cancer. BMJ Case Rep. 2025. https:\/\/doi.org\/10.1136\/bcr-2024-259660.","journal-title":"BMJ Case Rep"},{"issue":"10","key":"3222_CR43","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1038\/s43018-024-00822-0","volume":"5","author":"K Li","year":"2024","unstructured":"Li K, et al. Neoadjuvant gemcitabine-cisplatin plus Tislelizumab in persons with resectable muscle-invasive bladder cancer: a multicenter, single-arm, phase 2 trial. Nat Cancer. 2024;5(10):1465\u201378.","journal-title":"Nat Cancer"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03222-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-03222-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-03222-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T14:47:03Z","timestamp":1770389223000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-03222-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":43,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["3222"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-03222-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,30]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors agree to the publication of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was approved by the Ethics Committee of Zhejiang Cancer Hospital (Approval No.IRB-2023-470). All participants were recruited after they signed informed consent. All experimental procedures involving the animals were conducted in accordance with ethical standards and were approved by the Experimental Animal Ethical Committee of Zhejiang Cancer Hospital (Approval No.2024-09-020).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}}],"article-number":"107"}}